In a patient with mild hypercalcemia (serum calcium ~10.2 mg/dL), diffuse osteopenia, low 25‑hydroxy vitamin D, and recurrent renal calculi, what is the next step in management?

Measure Serum Intact Parathyroid Hormone (PTH) Immediately

The next step is to measure serum intact PTH to distinguish between PTH-dependent (primary hyperparathyroidism) and PTH-independent causes of hypercalcemia, as this single test will guide all subsequent management decisions 1, 2.

Diagnostic Algorithm

Why PTH is the Critical First Test

In any patient with hypercalcemia, PTH distinguishes the two major diagnostic pathways 1:

• Elevated or normal PTH = Primary hyperparathyroidism (PHPT)
• Suppressed PTH (<20 pg/mL) = PTH-independent causes (granulomatous disease, vitamin D disorders, malignancy)

This distinction is essential because approximately 90% of hypercalcemia cases are due to either PHPT or malignancy 1, 2. Your patient's presentation—mild hypercalcemia (10.2 mg/dL), recurrent kidney stones, osteopenia, and low vitamin D—is classic for PHPT, which typically presents with calcium <12 mg/dL, chronic duration (>6 months), kidney calculi, and metabolic bone disease 2, 3.

Clinical Context Supporting PHPT

The combination of:

• Recurrent nephrolithiasis (stones in PHPT often contain apatite salts plus calcium oxalate) 3
• Osteopenia (metabolic bone disease from chronic PTH excess)
• Mild hypercalcemia of likely long duration
• Low vitamin D (common in PHPT patients) 4

...makes PHPT the most likely diagnosis, but PTH measurement is mandatory for confirmation.

Critical Pitfall: Do NOT Supplement Vitamin D Before Measuring PTH

Hold vitamin D supplementation until after PTH is measured and the diagnosis is established. Here's why this is crucial:

If PHPT is Present (Elevated/Normal PTH):

Patients with PHPT and vitamin D deficiency can be treated with vitamin D, but require careful monitoring 4. The Endocrine Society guideline recommends treating to a 25(OH)D level of approximately 20–30 ng/mL (not the usual >30 ng/mL target), because higher levels may worsen hypercalciuria and hypercalcemia 4. Serum calcium must be monitored during treatment 4.

If PTH-Independent Cause is Present (Suppressed PTH):

This is where vitamin D supplementation becomes dangerous. Consider these scenarios:

• Granulomatous disease (sarcoidosis, tuberculosis): Activated macrophages produce 1,25(OH)₂D unregulated, causing hypercalcemia and hypercalciuria 4, 5. Vitamin D supplementation can precipitate severe hypercalcemia, nephrolithiasis, and renal impairment 5.

• CYP24A1 mutations: Genetic defects preventing 1,25(OH)₂D metabolism cause chronic hypercalcemia and nephrolithiasis 6, 7. These patients have inappropriately elevated 1,25(OH)₂D despite low 25(OH)D and suppressed PTH. Vitamin D supplementation worsens the condition 6.

One case report documented a patient who received a single 6000 µg cholecalciferol dose for low 25(OH)D in the setting of unrecognized granulomatous disease—this caused exacerbated hypercalcemia, nephrolithiasis, and renal impairment 5.

After PTH Results: Management Pathways

If PTH is Elevated or Normal (PHPT Confirmed):

1. Consider parathyroidectomy based on:

   • Age <50 years
   • Serum calcium >1 mg/dL above upper limit of normal
   • Evidence of skeletal disease (osteopenia present)
   • Evidence of kidney disease (recurrent stones present)

2. If observation chosen (age >50, calcium <1 mg above normal, no complications): Monitor calcium and bone density regularly

3. Vitamin D repletion: Target 25(OH)D of 20–30 ng/mL with calcium monitoring 4

If PTH is Suppressed (PTH-Independent):

1. Measure 1,25(OH)₂D levels to assess for excess production
2. Check 24,25(OH)D if available (very low suggests CYP24A1 mutation) 6
3. Evaluate for granulomatous disease: Chest imaging, ACE level, consider biopsy
4. Genetic testing for CYP24A1 if other causes excluded 6
5. Do NOT routinely supplement vitamin D in these patients 4, 5

Stone Prevention Considerations

While addressing the underlying hypercalcemia cause, note that increased fluid intake reduces stone recurrence risk by more than half 8. If PHPT is confirmed and surgery is not immediate, thiazides or citrate can reduce calcium stone recurrence 8, though thiazides must be used cautiously in hypercalcemia.